Loading...
•
Sep 30, 2020
Akebia Q3 2020 Earnings Report
Reported financial results and business updates for Q3 2020, including completion of a pre-NDA meeting with the FDA for vadadustat.
Key Takeaways
Akebia Therapeutics reported a total revenue of $60.0 million for the third quarter of 2020, compared to $92.0 million for the third quarter of 2019. The net loss for the quarter was $60.0 million, compared to $54.6 million for the same period in 2019. The company's cash, cash equivalents, and available-for-sale securities totaled $269.3 million as of September 30, 2020.
Presented positive global Phase 3 data for vadadustat from the INNO2VATE program at ASN Kidney Week.
Completed pre-NDA meeting with the FDA and remain on track to submit vadadustat NDA.
Launched vadadustat in Japan by Mitsubishi Tanabe Pharma Corporation (MTPC) as a treatment for anemia due to CKD.
Akebia and Otsuka launched Balancing Anemia Due to CKD, a campaign to increase awareness and education of anemia due to CKD among healthcare providers.
Akebia
Akebia
Akebia Revenue by Segment
Revenue by Segment
Auryxia Net Product Revenue
CapyFin.comLicense, Collaboration & Other Revenue
CapyFin.com Forward Guidance
Akebia plans to submit a New Drug Application (NDA) to the FDA for vadadustat as early as possible in 2021 for two indications: (1) the treatment of anemia due to CKD in adult patients on dialysis, and (2) the treatment of anemia due to CKD in adult patients not on dialysis.
Revenue & Expenses
Visualization of income flow from segment revenue to net income